Rasagiline alone and in combination with riluzole
prolongs survival in an ALS mouse model
by
Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph AC.
Department of Neurology, University of Ulm,
Oberer Eselsberg 45, 89081, Ulm, Germany.
J Neurol. 2004 Sep;251(9):1080-4.

ABSTRACT

Rasagiline is an antiapoptotic compound with neuroprotective potential. We examined its neuroprotective effect alone and in combination with the putative glutamate release blocker riluzole in the G93A model of familial amyotrophic lateral sclerosis (fALS). Endpoints of experimental treatment were survival and motor activity. The drug had a significant dose-dependent therapeutic effect on both preclinical and clinical motor function and survival of the animals. We also found that the combination of rasagiline with riluzole is safe and increases survival by about 20 % in a dosedependent manner. Therefore, we conclude that the combination of rasagiline and riluzole is a promising clinical combination for the improvement of current neuroprotective treatment strategies of ALS.

MAOIs
Rasagiline
Neuroprotection
Rasagiline: structure
MAO-b inhibitors/PD
Anti-apoptotic activity
Dopaminergic cell death
Parkinson's disease: resources
Anti-Alzheimer/anti-Parkinson's drugs
Parkinson's disease and sleep disorders
Rasagiline/ anti-apoptotic bcl-2 gene family
Dual AChE and MAO inhibitors and Alzheimer's
Rasagiline v selegiline: neuronal survival effects
Rasagiline (Agilect) in early Parkinson's disease

Refs
HOME
HedWeb
Selegiline.com
BLTC Research
Nootropics.com
The Good Drug Guide
Paradise-Engineering
Supercentenarians.com
The Hedonistic Imperative
MDMA: Utopian Pharmacology